The results of PPI network topology analysis showed that the therapeutic effect of this drug on hepatitis was mainly achieved by regulating RELA, AKT1, JUN, MAPK1, TP53, CCND1, MYC, RB1, MAPK14, NFKBIA, CDKN1A, HIF1A, ESR1, and FOS. This evidence concerns the gene CCND1 and hepatitis A virus infection.